CA209-9KY: Phase II Study of IMRT Re-Irradiation and Concurrent/Adjuvant Nivolumab (Nivo) in Patients With Loco Regionally Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC) ― Toxicity and Quality of Life (QoL) Results

Autor: Saba, N.F., Wong, S., Stokes, W.A., Rupji, M., Liu, Y., Rudra, S., Bates, J.E., Steuer, C., Remick, J.S., Cummings, K., Joshi, N.P., Woody, N.M., Geiger, J.L., Patel, M.R., Schmitt, N.C., El-Deiry, M.W., Chen, G., Wieland, A., Abazeed, M., Adelstein, D.J., Ahmed, R., Higgins, K.A., Beitler, J.J., Shin, D.M., Curran, W.J., Jr, McDonald, M.W., Koyfman, S.
Zdroj: In International Journal of Radiation Oncology, Biology, Physics 1 November 2021 111(3) Supplement:e361-e361
Databáze: ScienceDirect